Neoclease has been awarded a Golden Ticket from Chiesi Global Rare Diseases, granting us one year of lab space at BioLabs in Boston.
The award represents more than physical space. It is a vote of confidence in our approach to gene editing, which pairs synthetic biology with AI-driven enzyme design to build editors around a specific target rather than adapting one tool for every job.
The Golden Ticket gives us access to the facilities, resources, and mentorship at BioLabs, an ecosystem built for startups scaling innovative science. For Neoclease, that means an accelerated path to developing and validating our next-generation editors, and to making precision gene therapies safer, more effective, and more accessible.
This partnership aligns our work with Chiesi's mission in the rare disease community. We are grateful to Chiesi for the opportunity, and glad to keep building toward better outcomes for patients with genetic disease.